Compare Summit Therapeutics Inc (SMMT) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Unum Group Common Stock — how do they compare? Summit Therapeutics Inc trades at $15.03 (market cap $12.38B), while Unum Group Common Stock trades at $91.42 (market cap $14.57B). The key difference: Unum Group Common Stock is the larger of the two by market cap, and Unum Group Common Stock pays a 2.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Unum Group Common Stock for 0 Days on average.
| SMMT | UNM | |
|---|---|---|
Market Cap | $12.38B | $14.57B |
Volume | 7,111,626 | 1,461,588 |
Sector | Health | Financials |
52-Week High | $26.38 | $96.57 |
52-Week Low | $12.43 | $70.66 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $11.71B | $18.14B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
